Form 4: Tenaya CMO Granted Significant Equity Awards

Tenaya Therapeutics' Chief Medical Officer, Tingley Whittemore, received substantial restricted stock units and stock options under the company's 2021 Equity Incentive Plan.

Summary

• Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics, Inc. (TNYA), was granted equity awards on February 3, 2026.
• The awards include 48,750 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per unit.
• These RSUs will vest as to 1/8th of the total on August 15, 2026, and 1/8th every six months thereafter until fully vested.
• Following this transaction, the reporting person beneficially owns 223,778 shares of common stock, which includes 134,588 shares from previously granted RSUs.
• Additionally, 318,500 stock options were granted with an exercise price of $0.915 per share.
• These stock options will become exercisable as to 1/48th of the total on March 3, 2026 (one month anniversary of the transaction date), and 1/48th each monthly anniversary thereafter until fully vested.
• The stock options have an expiration date of February 2, 2036.
• Both the RSUs and stock options were granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as routine equity grants align management's financial interests with shareholder value creation, fostering long-term commitment and performance.

Positives

• The grant of restricted stock units and stock options aligns the Chief Medical Officer's interests with those of shareholders, incentivizing long-term company performance.
• The equity awards are part of a standard incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend several years into the future, indicating a long-term commitment and incentive structure for the Chief Medical Officer, with full vesting contingent on continued service and potential stock performance.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as restricted stock units and stock options, is a common and standard practice in the biotechnology and pharmaceutical industries. This compensation structure is widely used to attract, retain, and motivate key executives by linking their personal financial success to the long-term performance of the company's stock, thereby aligning management incentives with shareholder interests. Companies like Moderna, BioNTech, and Regeneron frequently utilize similar equity-based compensation plans for their executive teams.

Comparison to Industry Standards

• The use of a 2021 Equity Incentive Plan for executive compensation is a standard corporate governance practice, comparable to plans at other biotech firms like Vertex Pharmaceuticals or Gilead Sciences.
• The vesting schedules, with portions vesting over several years, are typical for executive equity grants, designed to encourage long-term retention and performance, similar to those observed at companies such as Amgen or Biogen.
• The grant of both restricted stock units (RSUs) and stock options is a common dual approach in executive compensation packages across the industry, providing both retention value (RSUs) and upside potential (options).

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are designed to align the Chief Medical Officer's incentives with shareholder interests, potentially leading to better long-term company performance.
• Employees: The compensation structure for a key executive may set a precedent or reflect the broader compensation philosophy within the company.

Next Steps

• The restricted stock units will begin vesting on August 15, 2026, with subsequent vesting every six months.
• The stock options will begin vesting on March 3, 2026, with subsequent vesting monthly.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Tingley Whittemore, Chief Medical Officer, Restricted Stock Units, RSU, Stock Options, Equity Incentive Plan, Insider Transaction, Executive Compensation